For research purposes only — not for human consumption — 18+ only
GH Peptides
CJC-1295 DAC 5mg
$100.00
Long-acting GHRH analogue with Drug Affinity Complex. Extended half-life for sustained GH release.
Use the peptide calculator to determine exact reconstitution volumes and dosing schedules for your research protocol.
Open Peptide Calculator ↗CJC-1295 with DAC (Drug Affinity Complex) incorporates a maleimidoproprionic acid (MPA) modification that enables covalent binding to circulating serum albumin in vivo. This albumin binding dramatically extends the effective half-life from ~30 minutes (No DAC version) to 6-8 days, fundamentally transforming the pharmacokinetic profile from a pulsatile to a sustained GH-stimulating compound. The DAC modification makes CJC-1295 the longest-acting GHRH analogue available for research, enabling once-weekly or even less frequent dosing in animal models.
Molecular Data
Modified GRF(1-29) with DAC (maleimidoproprionic acid) modification | Molecular Formula: C165H271N47O46S | Molecular Weight: 3647.28 g/mod
Albumin Binding Mechanism
The DAC modification adds a reactive maleimide group that forms a covalent thioether bond with the free cysteine-34 residue on serum albumin. Because albumin has a long half-life (~19 days in humans), CJC-1295 DAC is effectively protected from enzymatic degradation and renal clearance for the duration of albumin's circulatory lifetime. Active CJC-1295 is gradually released as albumin is catabolised, producing continuous GHRH receptor stimulation.
Sustained IGF-1 Elevation
Due to its prolonged action, CJC-1295 DAC produces sustained rather than pulsatile IGF-1 elevation. Studies demonstrate that a single injection maintains elevated IGF-1 for up to 2 weeks in animal models. This sustained IGF-1 profile is pharmacodynamically similar to exogenous GH administration and distinct from the pulsatile IGF-1 pattern produced by the No DAC version — making the two compounds useful for comparative research.
Once-Weekly Research Protocols
The 6-8 day half-life enables once-weekly dosing protocols in animal research, significantly simplifying experimental logistics compared to compounds requiring daily or multiple-daily administration. Steady-state IGF-1 levels are achieved within 2-3 weeks of weekly dosing, providing stable conditions for measuring downstream biological effects.
Pulsatile vs Sustained GH Research
A key research application of having both DAC and No DAC versions available is the ability to compare pulsatile versus sustained GH stimulation in matched experimental designs. Physiological GH secretion is pulsatile, and research suggests that the pulsatile pattern is important for certain downstream effects (such as GH receptor sensitivity maintenance). The DAC version allows investigation of what is lost or gained with sustained versus pulsatile stimulation.
Future Research
CJC-1295 DAC continues to be used in GH axis research, body composition studies, and investigations comparing the biological consequences of different GH stimulation patterns. Its once-weekly dosing makes it practical for long-duration animal studies.
Reviews
There are no reviews yet.